Scorpius Selected for Rapid Response Partnership Vehicle (RRPV) to Accelerate Medical Countermeasure Development in Support of BARDA
09 September 2024 - 2:30PM
Scorpius Holdings, Inc (NYSE
American: SCPX) (“Scorpius” or “the
Company”), an integrated contract development and manufacturing
organization ("CDMO"), today announced that it has been selected as
a member of the Biomedical Advanced Research and Development
Authority’s (BARDA) Rapid Response Partnership Vehicle (RRPV). The
RRPV supports BARDA in its mission to accelerate the development of
medical countermeasures (MCMs) to address emerging biological
threats such as pandemic influenza, infectious diseases, and other
public health emergencies.
As an active member of the RRPV, Scorpius will
collaborate with BARDA and other federal partners to support MCM
product and technology development in critical areas such as
vaccines and therapeutics. Scorpius’ extensive capabilities in
biomanufacturing and its state-of-the-art production facilities
should uniquely position it to meet the evolving needs of
government agencies tasked with responding to biological
threats.
“We are honored to have been selected for the
Rapid Response Partnership Vehicle,” said Jeff Wolf, CEO of
Scorpius Holdings. “This opportunity allows us to leverage our
manufacturing capabilities to support BARDA, the US government, and
groups that service the US government in rapidly addressing public
health emergencies. Our team is committed to accelerating the
development of medical countermeasures and delivering scalable
solutions to protect public health and national security.”
Scorpius’ facilities are equipped to handle the
production of biological products, offering both standard and
custom solutions for the development of biopharmaceuticals. The
company's manufacturing platform is designed for flexibility,
enabling swift responses to emerging health threats. By becoming
part of the RRPV, Scorpius expects to play an important role in
ensuring preparedness for future public health emergencies such as
pandemics and other biological risks.
BARDA, a division of the U.S. Department of
Health and Human Services’ Office of the Assistant Secretary for
Preparedness and Response (ASPR), works to support the development
of medical countermeasures such as vaccines, drugs, and diagnostic
tools to counteract health security threats. The inclusion of
Scorpius in the RRPV highlights the company’s ability to innovate
in the rapidly evolving landscape of biomanufacturing.
Scorpius Holdings, Inc.
Scorpius Holdings, Inc. is an integrated
contract development and manufacturing organization (CDMO) focused
on rapidly advancing biologic and cell therapy programs to the
clinic and beyond. Scorpius offers a broad array of analytical
testing, process development, and manufacturing services to
pharmaceutical and biotech companies at its state-of-the-art
facilities in San Antonio, TX. With an experienced team and new,
purpose-built U.S. facilities, Scorpius is dedicated to transparent
collaboration and flexible, high-quality biologics
biomanufacturing. For more information, please visit
www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. In some cases, forward-looking statements can be
identified by terminology such as "may," "should," "potential,"
"continue," "expects," "anticipates," "intends," "plans,"
"believes," "estimates," and similar expressions, and include
statements such as the collaboration expediting the development of
critical solutions for public health threats, including pandemic
preparedness and emerging infectious diseases; Scorpius
collaborating with BARDA and other federal partners to support MCM
product and technology development in critical areas such as
vaccines and therapeutics; Scorpius’ extensive capabilities in
biomanufacturing and its state-of-the-art production facilities
uniquely positioning it to meet the evolving needs of government
agencies tasked with responding to biological threats; the
opportunity allowing the Company to leverage our manufacturing
capabilities to support BARDA, the US government, and groups that
service the US government in rapidly addressing public health
emergencies; Scorpius playing an important role in ensuring
preparedness for future public health emergencies such as pandemics
and other biological risks by becoming part of the RRPV Important
factors that could cause actual results to differ materially from
current expectations include, among others, the ability of the
Company to, due to the collaboration, expedite the development of
critical solutions for public health threats, including pandemic
preparedness and emerging infectious diseases; the Company’s
ability to expand its large molecule biomanufacturing CDMO
services, attract new customers, profit from its pipeline and
continue to grow revenue; the ability to capture a meaningful
market share; the ability to generate meaningful cash flow and
become cash flow positive; the Company’s financing needs, its cash
balance being sufficient to sustain operations and its ability to
raise capital when needed, the Company’s ability to leverage fixed
costs and achieve long-term profitability; the Company’s ability to
obtain regulatory approvals or to comply with ongoing regulatory
requirements, regulatory limitations relating to the Company’s
ability to successfully promote its services and compete as a pure-
play CDMO, and other factors described in the Company’s annual
report on Form 10-K for the year ended December 31, 2023,
subsequent quarterly reports on Form 10-Qs and any other filings
the Company makes with the SEC. The information in this
presentation is provided only as of the date presented, and the
Company undertakes no obligation to update any forward-looking
statements contained in this presentation on account of new
information, future events, or otherwise, except as required by
law.
Media and Investor Relations
ContactDavid Waldman+1 919 289
4017ir@scorpiusbiologics.com
Scorpius (AMEX:SCPX)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Scorpius (AMEX:SCPX)
Historical Stock Chart
Von Dez 2023 bis Dez 2024